{
 "id": "obesity",
 "name": "Obesity",
 "aliases": [],
 "acronyms": [],
 "bodySystem": "endocrine",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 1
 },
 "funds": [
  {
   "fund": "Obesity",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 2000,
   "insuranceTypes": [
    "Any health insurance"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "SEMAGLUTIDE",
   "pages": [
    {
     "brand": "Ozempic",
     "url": "https://omnirx.org/negotiated-drugs/ozempic"
    }
   ],
   "labelSentence": "... o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22f5e548d0-cc79-4c34-a3f5-e20a5b8b6564%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Ozempic Savings (via NovoCare)",
     "url": "https://omnirx.org/assistance/ozempic-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Wegovy Savings (via NovoCare)",
     "url": "https://omnirx.org/assistance/wegovy-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Novo Nordisk PAP (NovoCare)",
     "url": "https://omnirx.org/assistance/novo-nordisk-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": "0.5 mg, 1 mg, or 2 mg",
     "listKind": "Available Products (PAP product list PDF)",
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 274,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Tirzepatide",
   "pages": [
    {
     "brand": "Mounjaro",
     "url": "https://omnirx.org/medicines/mounjaro"
    }
   ],
   "labelSentence": "... to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22487cd7e7-434c-4925-99fa-aa80b1cc776b%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Mounjaro Savings (via Lilly)",
     "url": "https://omnirx.org/assistance/mounjaro-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Diabetes Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/diabetes-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Liraglutide",
   "pages": [
    {
     "brand": "Victoza 3-Pak",
     "url": "https://omnirx.org/medicines/victoza-3-pak"
    }
   ],
   "labelSentence": "Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220b898330-eca1-f60a-71d2-b91716e336ed%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}